Cinnarizine

桂利嗪

Report date: 2023/02/28 20:00:44
NME

Base Information

Drug NameCinnarizine
Drug Alias Name桂益嗪cinarizina肉桂苯哌嗪cinnarizinecinnarizinum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistamine H1 receptor antagonists
TargetsHistamine H1 receptor
Therapy Area/IndicationsArteriosclerosisCerebral HemorrhageIntracranial Thrombosis +[4] 
Global Approved IndicationsArteriosclerosisCerebral HemorrhageIntracranial Thrombosis +[4] 
Approved Indications in ChinaArteriosclerosisCerebral HemorrhageIntracranial Thrombosis +[4] 
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Lisheng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArteriosclerosisCerebral HemorrhageIntracranial Thrombosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN07CA02
Related LinksWikipediaDrugBankKEGG